NCT02984852View on ClinicalTrials.gov

Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Healthy
Interventions
DRUG

Darunavir (DRV)

Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).

DRUG

Cobicistat (COBI)

Cobicistat 150 milligram (mg) will be taken orally in FDC together with DRV(800mg)/FTC(200mg)/TAF(10mg).

DRUG

Emtricitabine (FTC)

Emtricitabine 200 milligram (mg) will be taken orally in FDC together with COBI(150mg)/DRV(800mg)/TAF(10mg).

DRUG

Tenofovir Alafenamide (TAF)

Tenofovir Alafenamide 10 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/DRV(800mg).

Trial Locations (1)

Unknown

Tempe

All Listed Sponsors
lead

Janssen Scientific Affairs, LLC

INDUSTRY

NCT02984852 - Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants | Biotech Hunter | Biotech Hunter